Eric Hardter, Ph.D.

Eric Hardter, Ph.D., Associate Director, Regulatory Affairs at Boyds Consultants

Commentary
Cell and gene therapy rare disease drug development in the US – general principles, challenges and a landscape of mutual regulatory concession
2024-02-21T00:05:00
Cell and gene therapy rare disease drug development in the US – general principles, challenges and a landscape of mutual regulatory concession